StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.56+0.13 (+9.09%)

Close on Nov 18, 2026Market cap $66.85MP/E –Yield –

Acrivon Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Acrivon Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$62.92M. For fiscal 2025 it was -$63.67M. The highest annual figure on record is -$13.98M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$63.67M–
FY2024Dec 31, 2024-$65.67M–
FY2023Dec 31, 2023-$42.64M–
FY2022Dec 31, 2022-$30.12M–
FY2021Dec 31, 2021-$13.98M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.86M–
Q1 FY2026Mar 31, 2026-$20.54M–
Q4 FY2025Dec 31, 2025-$15.24M–
Q3 FY2025Sep 30, 2025-$12.28M–
Q2 FY2025Jun 30, 2025-$16.61M–
Q1 FY2025Mar 31, 2025-$19.54M–
Q4 FY2024Dec 31, 2024-$17.36M–
Q3 FY2024Sep 30, 2024-$17.32M–
Q2 FY2024Jun 30, 2024-$13.90M–
Q1 FY2024Mar 31, 2024-$17.08M–
Q4 FY2023Dec 31, 2023-$12.37M–
Q3 FY2023Sep 30, 2023-$9.81M–
Q2 FY2023Jun 30, 2023-$9.11M–
Q1 FY2023Mar 31, 2023-$11.36M–
Q4 FY2022Dec 31, 2022-$9.35M–
Q3 FY2022Sep 30, 2022-$6.52M–
Q2 FY2022Jun 30, 2022-$5.82M–
Q1 FY2022Mar 31, 2022-$8.42M–
Q4 FY2021Dec 31, 2021-$3.63M–

More Acrivon Therapeutics figures

See a number that looks wrong?